Articlenpj drug discovery2025

Preclinical characterization of EGT710, an oral non-peptidomimetic reversible covalent SARS-CoV-2 main protease inhibitor.

Stephanie A Moquin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.